Anne F Luetkemeyer
Overview
Explore the profile of Anne F Luetkemeyer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
2247
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Covington N, Luetkemeyer A, Imperial M, Dawson R, Cramer Y, Rosenkranz S, et al.
Pharmacogenet Genomics
. 2025 Feb;
PMID: 39960813
In Advancing Clinical Therapeutics Globally protocol A5372, a pharmacokinetic study of dolutegravir with 1-month of daily rifapentine/isoniazid, twice-daily dolutegravir offset the induction effects of rifapentine on plasma dolutegravir trough concentrations...
2.
Luetkemeyer A, Chew K, Lacey S, Hughes M, Harrison L, Daar E, et al.
Clin Infect Dis
. 2025 Feb;
PMID: 39960062
Background: Ensitrelvir, a severe acute respiratory syndrome coronavirus-2 main protease inhibitor, has demonstrated clinical and virologic efficacy in previous studies. Methods: In this global phase 3 trial, nonhospitalized adults with...
3.
Zhang B, Fong Y, Dang L, Fintzi J, Chen S, Wang J, et al.
Nat Commun
. 2025 Jan;
16(1):759.
PMID: 39824819
Neutralizing antibody titer has been a surrogate endpoint for guiding COVID-19 vaccine approval and use, although the pandemic's evolution and the introduction of variant-adapted vaccine boosters raise questions as to...
4.
Kim S, Can M, Agizew T, Auld A, Balcells M, Bjerrum S, et al.
PLoS Med
. 2025 Jan;
22(1):e1004502.
PMID: 39804959
Background: Globally, over one-third of pulmonary tuberculosis (TB) disease diagnoses are made based on clinical criteria after a negative bacteriological test result. There is limited information on the factors that...
5.
Sankaran M, Glidden D, Kohn R, Nguyen T, Bacon O, Buchbinder S, et al.
JAMA Intern Med
. 2025 Jan;
185(3):266-272.
PMID: 39761052
Importance: Increasing rates of sexually transmitted infections (STIs) have been associated with rises in serious morbidity. While doxycycline postexposure prophylaxis (doxyPEP), a strategy in which individuals take doxycycline, 200 mg,...
6.
Perkins R, Beima-Sofie K, Christopoulos K, Cohen S, Dright A, Dombrowski J, et al.
Sex Transm Dis
. 2024 Oct;
52(3):129-134.
PMID: 39481014
Background: Doxycycline post-exposure prophylaxis (doxy-PEP) reduces chlamydia, gonorrhea, and syphilis infections among men who have sex with men (MSM) and transwomen (TW). Perspectives of health care providers (HCPs) regarding doxy-PEP...
7.
Dombrowski J, Donnell D, Grabow C, Cohen S, Cannon C, Brown C, et al.
Clin Infect Dis
. 2024 Oct;
PMID: 39478321
Doxycycline post-exposure prophylaxis (doxy-PEP) reduces the risk of bacterial sexually transmitted infections (STIs) among men who have sex with men and transgender women. In the United States, doxy-PEP is in...
8.
Chu V, Glascock A, Donnell D, Grabow C, Brown C, Ward R, et al.
Nat Med
. 2024 Oct;
31(1):207-217.
PMID: 39363100
Doxycycline post-exposure prophylaxis (doxy-PEP) reduces bacterial sexually transmitted infections among men who have sex with men and transgender women. Although poised for widespread clinical implementation, the impact of doxy-PEP on...
9.
Fong Y, Dang L, Zhang B, Fintzi J, Chen S, Wang J, et al.
Clin Infect Dis
. 2024 Sep;
80(1):223-227.
PMID: 39325506
For COVAIL recipients of a coronavirus disease 2019 (COVID-19) Sanofi booster vaccine, neutralizing antibody titers were assessed as a correlate of risk (CoR) of COVID-19. Peak and exposure-proximal titers were...
10.
Litwin A, Tsui J, Heo M, Mehta S, Taylor L, Lum P, et al.
JAMA Netw Open
. 2024 Aug;
7(8):e2430024.
PMID: 39186268
Importance: Hepatitis C virus (HCV) reinfection after curative treatment remains a concern for people who inject drugs. Objective: To assess the incidence of HCV reinfection and associated risk factors. Design,...